Study of Crohn’s and ulcerative colitis treatment changes
Part of Digestive system clinical trials.
This study follows adults with Crohn’s disease or ulcerative colitis when their treatment is changed. It collects health information and samples to better understand how treatment changes affect people over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have Crohn’s disease or ulcerative colitis diagnosed at least 3 months ago
- Your treatment must have significantly changed recently (new dose, new medication, or a new treatment added)
- You must be able and willing to attend study visits and provide required questionnaires and samples
- You must speak and understand French, English, or German well enough for study tasks
- You must sign an informed consent form and you cannot be pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
This study looks for “biomarkers” (lab markers, like substances in blood or tissue) that may predict how Crohn’s disease or ulcerative colitis will go and how patients may respond. It may help doctors choose better monitoring or treatments in the future.
This study tests whether combining a specific diet with biologic medicines can reduce active inflammation and symptoms of Crohn’s disease. It may help people who still have active disease in the bowel despite prior care.
This study looks at how changes in gut bacteria (the microbiome) relate to inflammatory bowel disease, including ulcerative colitis and Crohn disease. It may help researchers understand what might improve symptoms or disease control.
This study looks at people with active Crohn's disease or ulcerative colitis starting a new type of medication (anti-TNF, ustekinumab, upadacitinib, or vedolizumab), as well as people without IBD having a routine colonoscopy. It aims to collect information to better understand how these treatments work.
This study collects samples to learn how gut microbes, genetics, and body chemistry may relate to Crohn’s disease or ulcerative colitis. Your information and samples may help researchers understand disease patterns, but it does not test a new drug.
Hear when a new Inflammatory Bowel Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.